Publication 9/01/2009

Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses.

Gao G, Wang Q, Calcedo R, Mays L, Bell P, Wang L, Vandenberghe LH, Grant R, Sanmiguel J, Furth EE, Wilson JM

Human Gene Therapy

Publication 7/01/2006

Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver.

Bell P, Moscioni AD, McCarter RJ, Wu D, Gao G, Hoang A, Sanmiguel JC, Sun X, Wivel NA, Raper SE, Furth EE, Batshaw ML, Wilson JM

Molecular Therapy : The Journal Of The American Society Of Gene Therapy

Publication 1/01/2002

A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency.

Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, Furth EE, Propert KJ, Robinson MB, Magosin S, Simoes H, Speicher L, Hughes J, Tazelaar J, Wivel NA, Wilson JM, Batshaw ML

Human Gene Therapy

Publication 3/20/1998

Selective gene transfer into the liver of non-human primates with E1-deleted, E2A-defective, or E1-E4 deleted recombinant adenoviruses.

Raper SE, Haskal ZJ, Ye X, Pugh C, Furth EE, Gao GP, Wilson JM

Human Gene Therapy

Publication 2/16/1996

Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors.

Ye X, Robinson MB, Batshaw ML, Furth EE, Smith I, Wilson JM

The Journal Of Biological Chemistry

Publication 5/10/1994

Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM

Proceedings Of The National Academy Of Sciences Of The United States Of America